Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD).

Next Previous
Trial Profile

Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease(REAL-CAD).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms REAL-CAD

Most Recent Events

  • 28 Aug 2023 Results (n=12,118) assessing Impact of worsening renal function (WRF) and baseline chronic kidney disease (CKD) on clinical outcomes in patients with chronic coronary syndromes presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 14 Sep 2022 Results (n=11105) assessing the relationship between very low on-treatment low-density lipoprotein cholesterol (LDL-C) level and cardiovascular event risk is still unclear in patients receiving the same doses of statins, published in the Circulation Journal.
  • 23 Jun 2021 Results of sub-study analysis assessing the effects on cardiovascular events in patients with stable coronary artery disease (CAD) and renal dysfunction, published in the American Heart Journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top